Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi.
Lymphocytic Leukemia, Chronic|Lymphoma, Small Lymphocytic
DRUG: IPI-145 (duvelisib)|DRUG: Obinutuzumab
Dose-limiting toxicities (DLTs), 28 days|Treatment-emergent adverse events (TEAEs), Up to 30 days from last dose of study treatment
Overall response rate (ORR), Up to 2 years from the first dose of study treatment|Duration of response (DOR), Up to 2 years from the first dose of study treatment|Progression-free survival (PFS), Up to 2 years from the first dose of study treatment|Overall survival (OS), Up to 2 years from the first dose of study treatment or until study treatment is completed, whichever is later|BTK mutation status, Baseline|Pharmacokinetic (PK) parameters of duvelisib and IPI-656 (major metabolite), Week 1, Week 2, Months 2, 4, 7, 11, 15, 19
This is a Phase 1b, open-label, dose escalation, safety and tolerability study of Duvelisib (IPI-145) in combination with obinutuzumab in subjects with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi therapy.